In a phase 1 trial of 59 adults with chronic HBV infection, 28 days of ALG-000184 (10–300 mg) versus placebo was well tolerated (TEAEs 58% vs 64%) and cut HBV DNA by about 3–4 log10 IU/mL; ALT rises were more frequent (31% vs 18%).
RCTn = 59
Yuen et al. ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial